Comparing the CD4 + T and CD8 + T lymphocytes according to clinical stages, it was noted that the intratumoral CD4 + T lymphocyte rate and CD4+/CD8 + T lymphocyte ratios significantly lower in patients with low stage NSCLC receiving neoajuvant therapy. Here, CD4 is linked to non-small cell lung carcinoma.